United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
WEST LAFAYETTE, Ind., May 03, 2017 -- Endocyte, Inc., (NASDAQ:ECYT) announced today that the company will host a conference call on Wednesday, May 10th, at 8:30 a.m. EDT to discuss its first quarter financial results and provide an operational update.
Investors and the general public are invited to listen to a live webcast of the call, which can be accessed in the Investors & News section of the Company’s website at www.endocyte.com or by dialing (877) 845-0711 (U.S./Canada) or (760) 298-5081 (International).
The webcast will be recorded and available on the Company’s website for 90 days following the call.
About Endocyte
Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer and other serious diseases. Endocyte uses its proprietary drug conjugation technology to create novel SMDCs and companion imaging agents for personalized targeted therapies. The company’s SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. For additional information, please visit Endocyte’s website at www.endocyte.com.
Contacts: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected]
